Dedagroup Stealth Acquires Zedonk
Dedagroup Stealth, the tech company behind more than 60% of Italy’s best-known global fashion brands, has acquired Zedonk, the company relied on by more than 650 small fashion businesses.
Until now, smaller brands and start-ups had no access to a single, integrated solution for managing the entire product life cycle, from initial design and production, right through to multichannel distribution in retail, wholesale, marketplaces and social commerce channels, and in addition they had no access to an Enterprise Resource Planning (ERP) technology to support rapid international growth. The acquisition of Zedonk by Dedagroup Stealth fills this market gap.
Dedagroup Stealth is one of only a handful of international companies with a wide range of software solutions for the efficient and flexible management of all the production and distribution processes for fashion products across multiple channels, which has given it leadership among large and medium-sized brands.
Now, with Zedonk, Dedagroup Stealth will be a unique partner for smaller fashion companies, from the very beginning of their growth trajectory right through to international expansion.
Zedonk enables brands in their emerging phase as well as those who are established, but want to accelerate their digital transformation journeys. Its solutions include design and production management, stock inventory, purchase orders, style management as well as customer and supplier relations, with all data managed and protected in the Cloud.
As well as complementary technologies, the two companies now have a significant footprint in the UK through new headquarters in London where Dedagroup Stealth consultants already on the ground will join the Zedonk team.
Marcia Lazar, Co-founder of Zedonk, said: "We join the Dedagroup Stealth family with great enthusiasm. For us, it is the ideal strategic partner to continue on our ambitious development path. We are truly satisfied with this global operation, which has the clear objective of bringing to the fashion sector an offer that can accompany any brand in every phase of its life, from the launch to the intermediate development phase up to maturity, supporting it in the definition of processes and strategies.”
Mimmo Solida, CEO of Dedagroup Stealth, added: “For too long, many brands have struggled to find an integrated solution that helps them manage their entire supply chain. It has long been our ambition to find a partner that can support designers, small brands and fashion start-ups as they grow, with a range of solutions that support business critical focuses of fashion retailers, from supply chain to sales, that allow for internationalisation. This acquisition will bring new value to the market and, at the same time, will strongly support our expansion strategy geographically and as a business, whilst completing our product portfolio to support fashion brands from entrepreneurial start-ups to enterprise players.”
Marco Podini, Executive Chairman of Dedagroup Stealth parent company Dedagroup, commented:"I am particularly pleased by the acquisition of Zedonk because our software, which has already contributed to the growth of many important creative brands in the world, can help other small fashion companies to develop rapidly. Our support is more vital than ever now that the market has changed so drastically for companies of all sizes, made even worse in the current crisis as whole countries shut down.”
“The global fashion industry needs the right tools to capitalise on business opportunities without being overwhelmed at an organisational level. The tsunami moving from east to west, leaving behind lowered shutters and people locked indoors, will be followed by a second wave that will see everyone wanting to get back to normal. Agility, underpinned by robust digital technologies, will be the catalyst that defines business success and will fuel retail performance in markets as they reopen, starting from China. Dedagroup Stealth will be able to support brands from the very smallest up to the largest as they restart their plans for global expansion,” Podini concluded.
-ENDS-
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005645/en/
Contact information
Sarah Cole
Head of PR at Fieldworks Marketing
sarah.cole@fieldworksmarketing.co.uk
07872 884 002
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
